KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Investments: 2009-2024

Historic Long-Term Investments for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $521.2 million.

  • Biomarin Pharmaceutical's Long-Term Investments fell 8.73% to $512.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.9 million, marking a year-over-year decrease of 8.73%. This contributed to the annual value of $521.2 million for FY2024, which is 14.71% down from last year.
  • Biomarin Pharmaceutical's Long-Term Investments amounted to $521.2 million in FY2024, which was down 14.71% from $611.1 million recorded in FY2023.
  • Biomarin Pharmaceutical's Long-Term Investments' 5-year high stood at $611.1 million during FY2023, with a 5-year trough of $285.5 million in FY2020.
  • Over the past 3 years, Biomarin Pharmaceutical's median Long-Term Investments value was $521.2 million (recorded in 2024), while the average stood at $488.7 million.
  • In the last 5 years, Biomarin Pharmaceutical's Long-Term Investments tumbled by 34.26% in 2022 and then spiked by 83.06% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Long-Term Investments stood at $285.5 million in 2020, then soared by 77.88% to $507.8 million in 2021, then tumbled by 34.26% to $333.8 million in 2022, then soared by 83.06% to $611.1 million in 2023, then declined by 14.71% to $521.2 million in 2024.